【文章摘要】 <正> Beijing SL Pharmaceuticals Co.,Ltd.(SZ:002038) announced on December 19th,2009 that it decided to acquire 40% equity in Nanjing KWDX Biological EngineeringTechnology Company Limited at a price of RMB 12 million.KWDX engages in the R&D of pharmaceutical intermediates,pharmaceutical activeingredients and pharmaceutical formulations and some small scale production.It achievedRMB2.15 million of sale revenue in the first eleven months of 2009,with a net profit ofRMB0.435 million.KWDX's R&D mainly focuses on triazole family drugs.SL Pharma is a gene drugs producer.It reported RMB283 million of sale revenue inthe first three quarters of 2009,an increase of 5.15% year over year.The net profitwas RMB189.6 million,up 18.23%.EPS was RMB0.76. |